Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 28;11(5):1239-1245.
doi: 10.14218/JCTH.2022.00067S. Epub 2023 Apr 28.

Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM

Affiliations
Review

Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM

Takashi Kobayashi et al. J Clin Transl Hepatol. .

Abstract

Drug-induced liver injury (DILI) is a major cause of acute liver injury, liver failure, and liver transplantation worldwide. In recent years, immune checkpoint inhibitors have become widely used. This has led to an increase in DILI, for which pathophysiology and management methods differ significantly from the past. As the number of cases of acute liver injury and liver transplantation due to DILI is expected to increase, information about a DILI is becoming more valuable. DILI is classified into two types according to its etiology: intrinsic DILI, in which the drug or its metabolites cause liver damage that is dose-dependent and predictable; and idiosyncratic DILI, in which liver damage is also dose-independent but unpredictable. In addition, depending on the course of the disease, chronic DILI or drug-induced autoimmune hepatitis may be present. The number of DILI cases caused by antimicrobial agents is decreasing, whereas that caused by drugs for malignant tumors and health foods is increasing. The Roussel Uclaf Causality Assessment Method is widely used to assess causality in DILI. Liver injury is a type of immune-related adverse event. The pattern of hepatic injury in immune-related adverse events is mostly hepatocellular, but mixed type and bile stasis have also been reported. Sclerosing cholangitis caused by immune checkpoint inhibitors has also been reported as a unique type of injury. Treatment mainly comprises withdrawal of immune checkpoint inhibitors and steroid administration; however, mycophenolate mofetil may be considered if the disease is refractory to steroids.

Keywords: Drug-induced liver injury; Immune checkpoint inhibitor; Immune-related adverse events; Updated RUCAM.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interests related to this publication.

Figures

Fig. 1
Fig. 1. Pharmacokinetics (ADME: Absorption, Distribution, Metabolism, Excretion).
Drugs are absorbed and distributed from the stomach and intestinal tract, transported via the portal vein to the liver and metabolized by hepatic enzymes before excretion. Pharmacokinetics is referred to as ADME from the initial letters of these four words (absorption, distribution, metabolism, and excretion).

Similar articles

Cited by

References

    1. Teschke R, Danan G. Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic DILI and 14,029 HILI cases published 1993-mid 2020: a comprehensive analysis. Medicines (Basel) 2020;7(10):62. doi: 10.3390/medicines7100062. - DOI - PMC - PubMed
    1. Weaver RJ, Blomme EA, Chadwick AE, Copple IM, Gerets HHJ, Goldring CE, et al. Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nat Rev Drug Discov. 2020;19(2):131–148. doi: 10.1038/s41573-019-0048-x. - DOI - PubMed
    1. Teschke R, Danan G. Idiosyncratic drug induced liver injury, cytochrome P450, metabolic risk factors and lipophilicity: highlights and controversies. Int J Mol Sci. 2021;22(7):3441. doi: 10.3390/ijms22073441. - DOI - PMC - PubMed
    1. Almazroo OA, Miah MK, Venkataramanan R. Drug metabolism in the liver. Clin Liver Dis. 2017;21(1):1–20. doi: 10.1016/j.cld.2016.08.001. - DOI - PubMed
    1. Suzuki E, Yamamura N, Ogura Y, Nakai D, Kubota K, Kobayashi N, et al. Identification of valproic acid glucuronide hydrolase as a key enzyme for the interaction of valproic acid with carbapenem antibiotics. Drug Metab Dispos. 2010;38(9):1538–1544. doi: 10.1124/dmd.110.032938. - DOI - PubMed